Histone lysine‐specific demethylase 1 (LSD1) is the first discovered and reported histone
demethylase by Dr. Shi Yang's group in 2004. It is classified as a member of amine oxidase …

There is increasing interest in targeting histone N-methyl-lysine demethylases (KDMs) with
small molecules both for the generation of probes for target exploration and for therapeutic …

Recently, despite the great success achieved by the so‐called “magic bullets” in the
treatment of different diseases through a marked and specific interaction with the target of …

Epigenetic modifications determine phenotypic characteristics in a reversible, stable and
genotype-independent manner. Epigenetic modifications mainly encompass CpG island …

The histone demethylase LSD1 is deregulated in several tumors, including leukemias,
providing the rationale for the clinical use of LSD1 inhibitors. In acute promyelocytic …

Due to the increasing costs and time consuming for new drug discovery, a large number of
pharmaceutical firms have chosen to modify the existing drug molecules for repositioning …

Since the first lysine-specific demethylase (KDM), lysine-specific demethylase 1 (LSD1), was
characterized in 2004, several families of KDMs have been identified. LSD1 can specifically …

The dynamic regulation of covalent modifications to histones is essential for maintaining
genomic integrity and cell identity and is often compromised in cancer. Aberrant expression …

Until 2004, many researchers believed that protein methylation in eukaryotic cells was an
irreversible reaction. However, the discovery of lysine-specific demethylase 1 in 2004 …

LSD1 is a histone lysine demethylase proposed as therapeutic target in cancer. Chemical
modifications applied at C2, C4 and/or C7 positions of the quinazoline core of the previously …